| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 990 | 2022 |
| Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ... Molecular Therapy 21 (11), 2122-2129, 2013 | 510 | 2013 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 458 | 2020 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 402 | 2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 367 | 2022 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959-1970, 2021 | 331 | 2021 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 318 | 2022 |
| Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy CFM Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, ... Blood, The Journal of the American Society of Hematology 125 (1), 71-81, 2015 | 241 | 2015 |
| Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ... Nature medicine 28 (4), 735-742, 2022 | 215 | 2022 |
| Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase … J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... The Lancet Oncology 22 (4), 512-524, 2021 | 185 | 2021 |
| Survival with axicabtagene ciloleucel in large B-cell lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine 389 (2), 148-157, 2023 | 173 | 2023 |
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect M Dickinson, RW Johnstone, HM Prince Investigational new drugs 28, 3-20, 2010 | 173 | 2010 |
| A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ... British journal of cancer 111 (6), 1072-1079, 2014 | 151 | 2014 |
| Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma M Dickinson, D Ritchie, DJ DeAngelo, A Spencer, OG Ottmann, T Fischer, ... British journal of haematology 147 (1), 97-101, 2009 | 114 | 2009 |
| Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy M Dickinson, R Hoyt, AW Roberts, A Grigg, JF Seymour, HM Prince, ... British journal of haematology 150 (1), 39-45, 2010 | 102 | 2010 |
| Romidepsin for cutaneous T-cell lymphoma HM Prince, M Dickinson Clinical Cancer Research 18 (13), 3509-3515, 2012 | 99 | 2012 |
| A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma SJ Harrison, H Quach, E Link, JF Seymour, DS Ritchie, S Ruell, J Dean, ... Blood, The Journal of the American Society of Hematology 118 (24), 6274-6283, 2011 | 97 | 2011 |
| Azacitidine with or without eltrombopag for first-line treatment of intermediate-or high-risk MDS with thrombocytopenia M Dickinson, H Cherif, P Fenaux, M Mittelman, A Verma, MSO Portella, ... Blood, The Journal of the American Society of Hematology 132 (25), 2629-2638, 2018 | 93 | 2018 |
| Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts B Reis, L Jukofsky, G Chen, G Martinelli, H Zhong, WV So, MJ Dickinson, ... Haematologica 101 (5), e185, 2016 | 89 | 2016 |
| Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin Lymphomas F Morschhauser, G Salles, P McKay, H Tilly, A Schmitt, J Gerecitano, ... Hematological Oncology 35, 24-25, 2017 | 83 | 2017 |
HM PrinceDirección de correo verificada de petermac.org
